Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis

Abstract

Tumour necrosis factor alpha (TNF alpha) is a critical inflammatory mediator in rheumatoid arthritis, and may therefore be a useful target for specific immunotherapy. In support of this hypothesis, we previously observed beneficial responses in patients with active rheumatoid arthritis after open-label administration of a chimeric monoclonal antibody to TNF alpha (cA2). We now report the results of a four-centre, randomised double-blind trial of a single infusion of 1 or 10 mg/kg cA2 compared with placebo in 73 patients with active rheumatoid arthritis. The primary endpoint of the study was the achievement at week 4 of a Paulus 20% response, an amalgam of six clinical, observational, and laboratory variables. Intention-to-treat analysis of data from individual patients showed only 2 of 24 placebo recipients responding at this time, compared with 11 of 25 patients treated with low-dose cA2 (p = 0.0083) and 19 of 24 patients treated with high-dose cA2 (p < 0.0001). Over half of the high-dose cA2 patients responded by the more stringent 50% Paulus criteria at this time (p = 0.0005). The magnitude of these responses was impressive, with maximum mean improvements in individual disease-activity assessments, such as tender or swollen-joint counts and in serum C-reactive protein, exceeding 60% for patients on high-dose treatment. There were two severe adverse events. 1 patient on 1 mg/kg cA2 developed pneumonia ("possibly" treatment-related) and 1 on 10 mg/kg had a fracture ("probably not" treatment-related). The results provide the first good evidence that specific cytokine blockade can be effective in human inflammatory disease and define a new direction for the treatment of rheumatoid arthritis.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(94)90628-9

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 24 references

Research works printed but not linked: 3

  1. Moreland, 1993, Double blind placebo-controlled phase II trial of diphtheria-interleukin-2 fusion toxin (DAB486IL-2) in patients with refractory rheumatoid arthritis (RA), Arthritis Rheum, 36, S39
  2. Moreland, 1993, Minimal efficacy of a depleting chimaeric anti-CD4 (cM-T412) in treatment of patients with refractory rheumatoid arthritis (RA) receiving concomitant methotrexate (MTX), Arthritis Rheum, 36, S39
  3. Pa van der Lubbe, Ba Dijkmans, Hm Markusse, et al., Lack of clinical effect of CD4 monoclonal antibody therapy in early rheumatoid arthritis: a placebo controlled trial, Arthritis Rheum ((in press)).

Cited by

See all 1,682

Metadata

Authors
Elliott, M. J., Maini, R. N., Feldmann, M., Kalden, J. R., Antoni, C., Smolen, J. S., Leeb, B., Breedveld, F. C., Macfarlane, J. D., Bijl, J. A., & Woody, J. N.
Affiliations
  • Hammersmith Hospital (GB)
  • Universitätsklinikum Erlangen (DE)
  • University of Pennsylvania Press (US)
Venue
The Lancet
Publisher
Elsevier BV
Published
1994-10
Volume
344
Issue
8930
Pages
1105-1110
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2142273705
Cited by
1,682
References
24
Citations by year
2026: 8 · 2025: 12 · 2024: 20 · 2023: 14 · 2022: 23 · 2021: 18 · 2020: 22 · 2019: 23 · 2018: 23 · 2017: 21 · 2016: 22 · 2015: 43 · 2014: 34 · 2013: 39 · 2012: 31
FWCI
63.21
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
  • Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
  • Health Sciences › Medicine › Complementary and alternative medicine › Natural Compounds in Disease Treatment
Keywords
rheumatoid arthritis, chimeric monoclonal antibody, CA2, TNF-α, TNF-alpha blockade, cytokine inhibition, disease activity, C-reactive protein, adverse events, pneumonia, fracture
MeSH terms
Infliximab, Adolescent, Adult, Aged, Antibodies, Monoclonal, Arthritis, Rheumatoid, Dose-Response Relationship, Immunologic, Double-Blind Method, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Pain Measurement, Placebos, Tumor Necrosis Factor-alpha, Antirheumatic Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. https://app.cochat.ai/papers/10.1016/s0140-6736(94)90628-9
The paper
Elliott, M. J., Maini, R. N., Feldmann, M., Kalden, J. R., Antoni, C., Smolen, J. S., Leeb, B., Breedveld, F. C., Macfarlane, J. D., Bijl, J. A., & Woody, J. N. (1994). Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. The Lancet. https://doi.org/10.1016/s0140-6736(94)90628-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.